MedTrace Logo

PArtial REbreathing for Migraine With Aura 1

NCT05546385 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2025-03-25

Study results available
· View outcomes & findings →

Summary

A prospective, multi-centre, randomized, double-blind, sham-controlled, parallel-group, group-sequential study to investigate safety and effectiveness of the Rehaler partial rebreathing device, in adults suffering from migraine with aura

Conditions

  • Migraine With Aura

Interventions

DEVICE

Partial Rebreathing Device

Partial Rebreathing Device

DEVICE

Sham breathing device

Sham breathing device

Sponsors & Collaborators

  • Qmed Consulting A/S

    collaborator INDUSTRY

  • Rehaler

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-08
Primary Completion
2024-10-30
Completion
2024-10-30

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05546385 on ClinicalTrials.gov